This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salhany, K. E. Articles by Collins, R. D. Search for Related Content PubMed PubMed Citation Articles by Salhany, K. E. Articles by Collins, R. D.

American Journal of Pathology, Vol 132, 265-277, Copyright © 1988 by American Society for Investigative Pathology

REGULAR ARTICLES

Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study

KE Salhany, JB Cousar, JP Greer, TT Casey, JP Fields and RD Collins
Division of Hematopathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232.

Some patients with cutaneous T cell lymphoma (CTCL) develop a high- grade, large-cell lymphoma associated with rapid deterioration of clinical status. This change in histologic appearance and clinical behavior of CTCL is similar to transformations of other hematopoietic and lymphoid neoplasms. From a group of 92 cases of CTCL, morphologic, immunologic and clinical features were studied in 17 cases of transformed CTCL. Transformation was noted, at presentation or subsequently, in either cutaneous or extracutaneous sites; remarkably, transformation was found at initial diagnosis of CTCL in 7 of 17 patients. T cell characteristics were maintained in all 17 cases of transformed CTCL; in 11 cases with complete phenotypes, there were 6 T- helper, 3 T-suppressor, and 2 aberrant T subtypes. The pre- and posttransformation phenotypes were similar in 3 of 7 cases tested over time (all T-helper); retention of T-suppressor phenotype was suggested in another case. T cell features were maintained in the other 3 cases, but the T subtypes were altered in 2 of these cases. Absent or diminished pan-T antigens (CD 5, CD 3, or UCHL1) were found in 9 of 17 cases. Leu-M1, Ki-1, or LN 2 antigens were expressed by transformed cells in 10 of 17 cases, often in patterns identical to Reed-Sternberg cells. Survival in patients with transformed CTCL was significantly shorter (median, 29 months) than in 44 CTCL patients without transformation (58 months, P = 0.015); survival after diagnosis of transformation was short (12 months). Patients with extracutaneous transformation had a shorter median survival after transformation (8 months) than those with transformation limited to skin (19 months). It is concluded that CTCL can transform morphologically to a large cell variant associated with aggressive behavior and shortened survival. Extracutaneous transformation apparently indicates a poorer prognosis than cutaneous transformation. Although transformed CTCL usually retains a T cell phenotype, some antigens are lost while other new antigens may be expressed. Recognition of transformed CTCL is facilitated by identification of the dysplastic cerebriform cell component, but often requires correlation of immunologic and clinical features.

This article has been cited by other articles:

				S. O. Arulogun, H. M. Prince, J. Ng, S. Lade, G. F. Ryan, O. Blewitt, and C. McCormack Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation Blood, October 15, 2008; 112(8): 3082 - 3087. [Abstract] [Full Text] [PDF]

				G. Quereux, S. Marques, J.-M. Nguyen, C. Bedane, M. D'incan, O. Dereure, E. Puzenat, A. Claudy, L. Martin, P. Joly, et al. Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sezary Syndrome Arch Dermatol, June 1, 2008; 144(6): 727 - 733. [Abstract] [Full Text] [PDF]

				E. Olsen, E. Vonderheid, N. Pimpinelli, R. Willemze, Y. Kim, R. Knobler, H. Zackheim, M. Duvic, T. Estrach, S. Lamberg, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Blood, September 15, 2007; 110(6): 1713 - 1722. [Abstract] [Full Text] [PDF]

				C. Fournel-Fleury, F. Ponce, P. Felman, A. Blavier, C. Bonnefont, L. Chabanne, T. Marchal, J. L. Cadore, I. Goy-Thollot, D. Ledieu, et al. Canine T-cell Lymphomas: A Morphological, Immunological, and Clinical Study of 46 New Cases Vet. Pathol., January 1, 2002; 39(1): 92 - 109. [Abstract] [Full Text] [PDF]

				H. Stein, H.-D. Foss, H. Durkop, T. Marafioti, G. Delsol, K. Pulford, S. Pileri, and B. Falini CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features Blood, December 1, 2000; 96(12): 3681 - 3695. [Abstract] [Full Text] [PDF]

				B. Vergier, A. de Muret, M. Beylot-Barry, L. Vaillant, D. Ekouevi, G. Chene, A. Carlotti, N. Franck, P. Dechelotte, P. Souteyrand, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases Blood, April 1, 2000; 95(7): 2212 - 2218. [Abstract] [Full Text] [PDF]

				E. Diamandidou, M. Colome-Grimmer, L. Fayad, M. Duvic, and R. Kurzrock Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis Blood, August 15, 1998; 92(4): 1150 - 1159. [Abstract] [Full Text] [PDF]